Home › Research › Drug development
Reduction in [18F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer's disease brain
Karim F, Ngo A, Danh TB, Delaney BA, Liang C, Serrano GE, Beach TG, Mukherjee J.. Brain research, 2025-03-26
Topic: Brain proteins, microglia and lab models
Plain-language summary
Nicotinic acetylcholinergic receptors (nAChRs), including the α4β2* subtype are involved in cognition, learning and memory and may be adversely affected in Alzheimer's disease (AD). In our efforts to consider translational use of [ 18 F]nifene PET in AD, we report quantitative autoradiographic evaluation of α4β2* nAChRs using hippocampus-subiculum (HP-SUB) from cognitively normal (CN) and AD subjects. Brain slices were incubated in [ 18 F]nifene for α4β2* nAChRs and adjacent sections were tested with [ 18 F]flotaza for Aβ plaques and [ 125 I]IPPI for tau. Anti-Aβ and anti-tau immunostaining were carried out on adjacent slices. Regions of interest were drawn and binding of [ 18 F]nifene, [ 18 F]flotaza and [ 125 I]IPPI were quantified.All CN subjects exhibited significant [ 18 F]nifene binding in the HP-SUB regions. Average [ 18 F]nifene ratios of SUB to HP was 1.9, suggesting higher α4β2* nAChRs in the SUB versus HP regions. [ 18 F]nifene binding did not change with aging in the female subjects, while the male subjects exhibited a weak positive correlation. There was a significant decrease in the binding of [ 18 F]nifene in AD subjects compared to CN. Braak stage comparisons showed a decrease of [ 18 F]nifene in stages V and VI, while [ 18 F]flotaza and [ 125 I]IPPI increased significantly. A negative correlation was observed between [ 18 F]nifene vs [ 18 F]flotaza and [ 18 F]nifene vs [ 125 I]IPPI across Braak stages I-VI. These findings suggest that α4β2* nAChR availability was effectively measured by [ 18 F]nifene in the HP-SUB and was adversely affected by the presence of Aβ plaques and tau.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Karim, F., Ngo, A., Danh, T. B., Delaney, B. A., Liang, C., Serrano, G. E., et al. (2025). Reduction in [18F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer's disease brain. Brain research. https://doi.org/10.1016/j.brainres.2025.149600
Vancouver
Karim F, Ngo A, Danh TB, Delaney BA, Liang C, Serrano GE, et al. Reduction in [18F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer's disease brain. Brain research. 2025. doi:10.1016/j.brainres.2025.149600. PMID: 40154862.
BibTeX
@article{karim2025-40154862,
author = {Karim, F. and Ngo, A. and Danh, T. B. and Delaney, B. A. and Liang, C. and Serrano, G. E. and Beach, T. G. and Mukherjee, J.},
title = {{Reduction in [18F]Nifene Binding, a PET imaging Probe for α4β2* Nicotinic acetylcholinergic receptors in Hippocampus-Subiculum of postmortem human Alzheimer's disease brain}},
journal = {Brain research},
year = {2025},
doi = {10.1016/j.brainres.2025.149600},
pmid = {40154862},
url = {https://doi.org/10.1016/j.brainres.2025.149600}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Regions of interest were drawn and binding of [ 18 F]nifene, [ 18 F]flotaza and [ 125 I]IPPI were quantified.All CN subjects exhibited significant [ 18 F]nifene binding in the HP-SUB regions.
- Average [ 18 F]nifene ratios of SUB to HP was 1.9, suggesting higher α4β2* nAChRs in the SUB versus HP regions. [ 18 F]nifene binding did not change with aging in the female subjects, while the male subjects exhibited a weak positive correlation.
- There was a significant decrease in the binding of [ 18 F]nifene in AD subjects compared to CN.
- Braak stage comparisons showed a decrease of [ 18 F]nifene in stages V and VI, while [ 18 F]flotaza and [ 125 I]IPPI increased significantly.
- These findings suggest that α4β2* nAChR availability was effectively measured by [ 18 F]nifene in the HP-SUB and was adversely affected by the presence of Aβ plaques and tau.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 26 of the 58 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40154862) |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 26 of the 58 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “nicotinic”
2 studies in the library carry the topic tag “nicotinic”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.